Since it was first described by international health organizations in 2006, extensively drug-resistant tuberculosis has been documented in 49 countries. In addition, more than 80 countries are coping with multi-drug resistant tuberculosis. How are we addressing the rapid emergence of these significant threats to tuberculosis treatment and control programs across the world? In which countries are we seeing significant progress in treating both forms of tuberculosis? Dr. Sonya Shin, assistant professor of medicine at Harvard Medical School, contours lessons for the global struggle against TB from her work in South America and Asia with host Dr. Mark Nolan Hill.
ReachMD
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Successful Treatment of MDR and XDR-TB
Share this program on:
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
Presenters
Recommended
Details
Presenters
Comments
Recommended
Overview
Since it was first described by international health organizations in 2006, extensively drug-resistant tuberculosis has been documented in 49 countries. In addition, more than 80 countries are coping with multi-drug resistant tuberculosis. How are we addressing the rapid emergence of these significant threats to tuberculosis treatment and control programs across the world? In which countries are we seeing significant progress in treating both forms of tuberculosis? Dr. Sonya Shin, assistant professor of medicine at Harvard Medical School, contours lessons for the global struggle against TB from her work in South America and Asia with host Dr. Mark Nolan Hill.
Presenters
Facebook Comments